DCPRIME

dcprime-logo

DCPrime is a clinical-stage cancer immunotherapy company, which develops therapeutic vaccines based on its proprietary DCOne platform. DCOne‐based vaccines share all immune‐stimulatory properties with patient-derived dendritic cell‐based vaccines, and have the simple logistics of off‐the‐shelf products. DCOne cells express a range of known tumor antigens, which are targeted in several cancer types.

#SimilarOrganizations #People #Financial #Website #More

DCPRIME

Social Links:

Industry:
Biotechnology Clinical Trials Therapeutics

Founded:
2006-01-01

Address:
Leiden, Zuid-Holland, The Netherlands

Country:
The Netherlands

Website Url:
http://www.dcprime.nl

Total Employee:
11+

Status:
Active

Email Addresses:
[email protected]

Total Funding:
26.53 M USD

Technology used in webpage:
SPF Microsoft Exchange Online Office 365 Mail Microsoft Azure DNS Barracuda Networks Realtime Register


Similar Organizations

alpha-o-peptides-logo

Alpha-O Peptides

Alpha-O Peptides are focusing on the development of potent vaccines based on repetitive antigen display technology.

gritstone-bio-logo

Gritstone Bio

Gritstone Oncology is a clinical-stage biotech company that develops tumor-specific cancer immunotherapies to fight multiple cancer types.

hookipa-pharma-logo

Hookipa Pharma

Hookipa is a clinical stage biotech company developing best-in-class active immunization therapies for infectious diseases and oncology.

immutep-logo

Immutep

Immutep is a biopharmaceutical company developing immunotherapeutics in oncology.

proteostasis-therapeutics-logo

Proteostasis Therapeutics

Proteostasis Therapeutics is a clinical stage biopharmaceutical company developing small molecule therapeutics to treat cystic fibrosis.

viamune-logo

ViaMune

ViaMune is a preclinical-stage company with a mission to enable immunotherapy for patients with advanced cancers.

Current Employees Featured

jeroen-rovers_image

Jeroen Rovers
Jeroen Rovers Chief Medical Officer @ DCPrime
Chief Medical Officer

erik-manting_image

Erik Manting
Erik Manting CEO @ DCPrime
CEO

ada-kruisbeek_image

Ada Kruisbeek
Ada Kruisbeek Chief Scientific Officer @ DCPrime
Chief Scientific Officer
2018-03-01

Founder


ada-kruisbeek_image

Ada Kruisbeek

Investors List

van-herk-ventures_image

Van Herk Ventures

Van Herk Ventures investment in Venture Round - DCPrime

horizon-2020_image

Horizon 2020

Horizon 2020 investment in Grant - DCPrime

van-herk-ventures_image

Van Herk Ventures

Van Herk Ventures investment in Corporate Round - DCPrime

skylinedx_image

SkylineDx

SkylineDx investment in Corporate Round - DCPrime

thuja-capital_image

Thuja Capital

Thuja Capital investment in Venture Round - DCPrime

Official Site Inspections

http://www.dcprime.nl

  • Host name: server010.yourhosting.nl
  • IP address: 185.37.71.24
  • Location: Netherlands
  • Latitude: 52.3824
  • Longitude: 4.8995
  • Timezone: Europe/Amsterdam

Loading ...

More informations about "DCPrime"

DCPrime - Crunchbase Company Profile & Funding

Contact Email [email protected] DCPrime is a clinical-stage cancer immunotherapy company, which develops therapeutic vaccines based on its proprietary DCOne platform. DCOne‐based …See details»

Company – DCprime

DCprime is a clinical-stage cancer immunotherapy company shaping the field of relapse vaccines. At DCprime, we are committed to develop therapeutic vaccines to delay or prevent cancer …See details»

Home – DCprime

Dec 7, 2020 Leiden, The Netherlands, November 5, 2020 – DCprime, the front-runner in the field of relapse vaccines, today announced the upcoming oral presentation of interim results from its ongoing Phase II clinical trial …See details»

DCprime | Leiden [TransFirm]

De stichting met de naam DCprime is ingeschreven bij de Kamer van Koophandel (KvK) onder nummer 34224535 is gevestigd op het adres Emmy Noetherweg 2K in de woonplaats Leiden …See details»

DCPrime Company Profile 2024: Valuation, Investors, Acquisition

DCPrime General Information Description. Provider of novel cancer immunotheraputic services based out of Leiden, Netherlands. The company's immunotherapies combines antigen carrier …See details»

DCPrime BV - Leiden, Netherlands - bionity.com

Oct 11, 2012 dcprime.nl +31 71 332 2626. Share. Xing Linkedin Facebook X E-mail Loading... Bookmark. Bookmark list; Bookmark. DCPrime BV. Galileiweg 8 2333 BD Leiden Netherlands …See details»

DCprime Company Profile - Office Locations, Competitors ... - Craft

DCprime has 5 employees at their 1 location. See insights on DCprime including office locations, competitors, revenue, financials, executives, subsidiaries and more at Craft.See details»

DCPrime and apceth Biopharma GmbH announce manufacturing …

Leiden, The Netherlands, and Munich, Germany – DCPrime BV, a clinical stage company developing dendritic cell vaccines to treat cancer, and apceth Biopharma GmbH, an …See details»

DCPrime - Funding, Financials, Valuation & Investors - Crunchbase

How much funding has this organization raised over time? Show . Announced Date . Transaction Name . Number of Investors . Money Raised . Lead Investors . Access exclusive financial …See details»

☑️DCPrime B.V. — Consulting Organization from the …

DCPrime B.V. — Consulting Organization from the Netherlands, has experience with Horizon 2020 (2014 - 2020), it`s involved in Health sectorSee details»

Immunicum AB (publ) Completes Business Combination with

Dec 21, 2020 Immunicum AB (publ; IMMU.ST) ("Immunicum" or the "Company") today completed the business combination with DCPrime BV, a Dutch clinical stage company …See details»

DCprime - Kempen

DCprime’s lead product, DCP-001, is a whole-cell-based vaccine addressing blood cancers with a high risk of relapse, currently in Phase II trials in AML. DCprime is pursuing similar vaccination …See details»

Immunicum AB and DCprime Combine Forces to Establish Leader …

Nov 23, 2020 Immunicum AB (publ) (IMMU.ST) announced that it has entered into an agreement with Van Herk Investments B.V. to acquire all of the shares in DCprime B.V., a …See details»

Immunicum AB and DCprime Combine Forces to Establish Leader …

Press Release 18 November 2020Immunicum AB and DCprime Combine Forces to Establish Leader in Cell-Based Cancer Immunotherapies\\-- Synergistic combination of each company’s …See details»

DC Prime CEO Ada M. Kruisbeek interview - YouTube

Feb 2, 2016 DCPrime BV and EUFETS GmbH unite forces in an Eurostars project, co-funded by EUREKA and the European Commission, to develop the first technology platform in...See details»

DCprime Strengthens Supervisory Board with the Additions of …

Leiden, The Netherlands, April 25, 2019 – DCprime, the front-runner in the field of relapse vaccines, today announced the appointment of two highly-experienced industry veterans, …See details»

DCprime Presents Comprehensive Preclinical Results Supporting …

May 14, 2019 DCprime, the front-runner in the field of relapse vaccines, today announced presentations of additional preclinical data sets for its lead program, DCP-001, at the 7th …See details»

DCPrime and VUmc awarded €6 million Euro Horizon2020 grant – …

DCPrime and VUmc awarded Horizon2020 grant to support the development of a dendritic-cell vaccine therapy for Acute Myeloid Leukemia. DCPrime, a Dutch cancer immunotherapy …See details»

DCprime: first patient dosed in phase 2 study - HollandBIO

Nov 15, 2018 DCprime, a clinical stage biotechnology company focused on cancer immunotherapies, announces that the first patient has been dosed with DCP-001 in a phase 2 …See details»

DCPrime obtains patent protection for DCOne® platform – DCprime

DCPrime obtains broad patent protection in the EU for proprietary DCOne ® platform. DCPrime, a clinical stage cancer immunotherapy company, has been granted a European patent on its …See details»

linkstock.net © 2022. All rights reserved